- Record: found
- Abstract: found
- Article: not found
Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause.
Chiara Bondi
1
,
2 ,
Simone Ferrero
1
,
2 ,
Carolina Scala
1
,
2 ,
Emanuela Tafi
1
,
2 ,
Annalisa Racca
1
,
2 ,
Pier Luigi Venturini
1
,
2 ,
Umberto Leone Roberti Maggiore
1
,
2
Oct 2016
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Ospemifene is a selective estrogen receptor modulator recently approved by the FDA for the treatment postmenopausal women experiencing moderate-to-severe dyspareunia and by the EMA for the treatment of moderate-to-severe symptomatic genitourinary syndrome of menopause (GSM) in women who are not suitable candidates for local vaginal estrogen therapy.